SS Innovations to Uplist to Nasdaq

Core Viewpoint - SS Innovations International, Inc. has received approval for its common stock to be listed on The Nasdaq Capital Market, with trading expected to commence on April 25, 2025, under the ticker symbol "SSII" [1][2] Company Overview - SS Innovations is focused on developing innovative surgical robotic technologies aimed at making robotic surgery affordable and accessible globally [4] - The company is headquartered in India and plans to expand its global presence with advanced, user-friendly, and cost-effective surgical robotic solutions [4] Product Information - The SSi Mantra Surgical Robotic System is a modular, multi-arm system featuring advanced technology such as 3 to 5 robotic arms, a 3D 4K monitor, and over 40 types of robotic endo-surgical instruments [5] - The SSi Mantra has been clinically validated in over 100 different types of surgical procedures in India [5] Recent Achievements - The company has installed 80 SSi Mantra systems in 75 hospitals across India and other countries, performing over 3,500 surgeries, including 195 robotic cardiac surgeries with no reported device-related complications [7] - SS Innovations is the first company in India to receive regulatory approval for telesurgery and tele-proctoring procedures, having conducted 16 telesurgeries, including the world's first robotic cardiac telesurgeries over distances up to 1,200 miles [7] - For the year ended December 31, 2024, the company reported revenue of $20.6 million, a 251% increase from $5.9 million in 2023, with a gross margin of 40.9%, up from 12.3% in 2023 [7][8] Strategic Expansion - The uplisting to Nasdaq coincides with the company's global expansion plans into countries such as Nepal, Ecuador, Guatemala, the Philippines, Indonesia, Sri Lanka, and Ukraine, as well as strategic entry into Europe and the United States [3] - The company is pursuing EU CE Mark and U.S. FDA approval for the SSi Mantra surgical robotic system, anticipated in late 2025 and early 2026, respectively [3]